苑東生物(688513.SH):擬使用不超6億元暫時閒置募集資金進行現金管理
格隆匯3月28日丨苑東生物(688513.SH)公佈,2022年3月28日,公司召開第三屆董事會第二次會議和第三屆監事會第二次會議審議通過了《關於使用暫時閒置募集資金進行現金管理的議案》,同意公司在確保不影響募集資金安全和投資項目資金使用進度安排的前提下,使用不超過6億元(包含本數)的暫時閒置募集資金進行現金管理,用於購買安全性高、流動性好的投資產品(包括但不限於結構性存款、定期存款、大額存單、證券公司保本型收益憑證、國債逆回購等),在上述額度範圍內,資金可以滾動使用,使用期限不超過董事會審議通過之日起18個月。提請董事會授權董事長行使該項決策權及簽署相關法律文件,具體事項由公司財務部負責組織實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.